Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study

被引：0
|
作者：
Deodhar, Atul [1 ]
Gossec, Laure [2 ,3 ]
Mease, Philip [4 ]
Coarse, Jason [5 ]
Edens, Heather [6 ]
De Peyrecave, Natasha [7 ]
Assudani, Deepak [7 ]
Ink, Barbara [7 ]
Ritchlin, Christopher [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Sorbonne Univ, Paris, France
[3] Hop Univ Pitie Salpetriere, Paris, France
[4] Seattle Rheumatol Associates PLLC, Seattle, WA USA
[5] UCB Pharma, Raleigh, NC USA
[6] UCB Pharma, Smyrna, GA USA
[7] UCB Pharma, Slough, Berks, England
[8] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0906
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Ritchlin, Christopher T.
    Kavanaugh, Arthur
    Merola, Joseph F.
    Schett, Georg
    Scher, Jose U.
    Warren, Richard B.
    Gottlieb, Alice B.
    Assudani, Deepak
    Bedford-Rice, Kathy
    Coarse, Jason
    Ink, Barbara
    McInnes, Iain B.
    LANCET, 2020, 395 (10222): : 427 - 440
  • [2] Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
    Gossec, Laure
    Mease, Philip
    Gottlieb, Alice
    Assudani, Deepak
    Coarse, Jason
    Ink, Barbara
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [3] Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
    Mease, Philip
    Tillett, William
    de Wit, Maarten
    Gossec, Laure
    Husni, M. Elaine
    Proft, Fabian
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Coates, Laura
    Gottlieb, Alice
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4789 - 4792
  • [4] Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naive or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
    Husni, M. Elaine
    Mease, Philip J.
    Merola, Joseph
    Behrens, Frank
    Favalli, Ennio Giulio
    McGonagle, Dennis
    Tillett, William
    Tsuji, Shigeyoshi
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Gossec, Laure
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4197 - 4199
  • [5] Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active PsA: Overall and TNF-inhibitor-naive population results from a 48-week Phase 2b randomized study
    Merola, Joseph F.
    Kavanaugh, Arthur
    Schett, Georg
    Scher, Jose U.
    Warren, Richard B.
    Assudani, Deepak
    Kumke, Thomas
    Ink, Barbara
    McInnes, Iain
    Ritchlin, Christopher
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB48 - AB48
  • [6] DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY
    Ritchlin, Christopher T.
    Kavanaugh, Arthur
    Merola, Joseph F.
    Schett, Georg
    Scher, Jose U.
    Warren, Richard B.
    Assudani, Deepak
    Kumke, Thomas
    Ink, Barbara
    Mcinnes, Iain
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 127 - 128
  • [7] Bimekizumab Safety and Efficacy in Patients with Psoriatic Arthritis: 3-Year Results from a Phase 2b Open-Label Extension Study
    Coates, L. C.
    Warren, R. B.
    Ritchlin, C. T.
    Gossec, L.
    Merola, J. F.
    Assudani, D.
    Coarse, J.
    Eells, J.
    Ink, B.
    McInnes, I. B.
    SWISS MEDICAL WEEKLY, 2021, 151 : S20 - S20
  • [8] BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2B OPEN-LABEL EXTENSION STUDY
    Coates, L. C.
    Warren, R. B.
    Ritchlin, C. T.
    Gossec, L.
    Merola, J. F.
    Assudani, D.
    Coarse, J.
    Eells, J.
    Ink, B.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 779 - 780
  • [9] BIMEKIZUMAB TREATMENT RESULTED IN IMPROVEMENTS IN FATIGUE AND PAIN IN BIOLOGIC DMARD-NAIVE OR TNFI-IR PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED 16-WEEK RESULTS FROM TWO PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDIES
    Rischmueller, Maureen
    Husni, M. Elaine
    Mease, Philip J.
    Merola, Joseph F.
    Behrens, Frank
    Favalli, Ennio G.
    McGonagle, Dennis
    Tillett, William
    Tsuji, Shigeyoshi
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Gossec, Laure
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
  • [10] Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
    Mease, Philip
    Gossec, Laure
    Coates, Laura
    Gottlieb, Alice B.
    Assudani, Deepak
    Ink, Barbara
    Coarse, Jason
    Irvin-Sellers, Oscar
    Gladman, Dafna
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345